Crisugabalin for Radiotherapy-Related Neuropathic Pain

This trial is testing crisugabalin — a newer nerve pain medication — for people who develop chronic nerve pain (neuropathic pain) after receiving radiation therapy for head and neck cancer. This type of pain is common after radiotherapy and can be difficult to treat. **You may be eligible if...** - You are 18 or older and have been diagnosed with a head or neck tumor that was treated with radiation at least 6 months ago - You are experiencing pain (average score of 4 or more out of 10) in areas related to your radiation treatment, such as the head, face, neck, or arms - Your pain has been diagnosed as neuropathic (nerve pain) lasting at least 4 weeks, confirmed by two neurologists - You are expected to live at least 5 months - Your thinking and communication are clear enough to participate **You may NOT be eligible if...** - You are currently on certain other nerve pain medications that may conflict with the study drug - You have severe kidney or liver problems - You have a history of drug abuse or dependence - Your pain is not neuropathic in nature Talk to your doctor to see if this trial is right for you.